GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Cyclically Adjusted PB Ratio

BriaCell Therapeutics (BriaCell Therapeutics) Cyclically Adjusted PB Ratio : 0.30 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-21), BriaCell Therapeutics's current share price is $1.49. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 was $4.95. BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is 0.30.

The historical rank and industry rank for BriaCell Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

BCTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.66
Current: 0.28

During the past years, BriaCell Therapeutics's highest Cyclically Adjusted PB Ratio was 0.66. The lowest was 0.00. And the median was 0.00.

BCTX's Cyclically Adjusted PB Ratio is ranked better than
80.25% of 648 companies
in the Biotechnology industry
Industry Median: 1.745 vs BCTX: 0.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share data for the three months ended in Jan. 2024 was $-0.505. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.95 for the trailing ten years ended in Jan. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.14 0.12 0.23 0.52

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.45 0.52 0.50 0.83

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.



BriaCell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.49/4.95
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book=Book Value per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.505/125.0724*125.0724
=-0.505

Current CPI (Jan. 2024) = 125.0724.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201404 136.960 98.920 173.169
201407 -0.017 99.315 -0.021
201410 10.337 99.473 12.997
201501 5.879 98.209 7.487
201504 5.474 99.710 6.866
201507 4.104 100.579 5.103
201510 3.091 100.500 3.847
201601 1.848 100.184 2.307
201604 3.733 101.370 4.606
201607 2.586 101.844 3.176
201610 4.837 102.002 5.931
201701 4.082 102.318 4.990
201704 4.469 103.029 5.425
201707 2.125 103.029 2.580
201710 2.633 103.424 3.184
201801 1.254 104.056 1.507
201804 4.465 105.320 5.302
201807 1.784 106.110 2.103
201810 0.673 105.952 0.794
201901 -1.109 105.557 -1.314
201904 0.982 107.453 1.143
201907 -1.053 108.243 -1.217
201910 -1.130 107.927 -1.310
202001 -3.133 108.085 -3.625
202004 -3.817 107.216 -4.453
202007 -4.982 108.401 -5.748
202010 -4.364 108.638 -5.024
202101 -4.704 109.192 -5.388
202104 1.834 110.851 2.069
202107 1.812 112.431 2.016
202110 3.604 113.695 3.965
202201 2.991 114.801 3.259
202204 2.952 118.357 3.120
202207 0.666 120.964 0.689
202210 0.666 121.517 0.685
202301 -0.083 121.596 -0.085
202304 -0.380 123.571 -0.385
202307 -0.236 124.914 -0.236
202310 0.170 125.310 0.170
202401 -0.505 125.072 -0.505

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (NAS:BCTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BriaCell Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus

BriaCell to Investigate Alleged Illegal Trading of Public Securities

By Stock market mentor Stock market mentor 01-23-2023